Assessment of Thiosemicarbazone‐Containing Compounds as Potential Antileukemia Agents against P‐gp Overexpressing Drug Resistant K562/A02 Cells
作者:Xiaoke Gu、Mingyu Guan、Chunyu Jiang、Qinghua Song、Xin Li、Nan Sun、Jing Chen、Jingying Qiu
DOI:10.1002/cbdv.202000775
日期:2021.2
for leukemia. In this study, seventeen thiosemicarbazone-containing compounds were prepared and evaluated as potential anti-leukemia agents against drug resistant K562/A02 cell overexpressing P-gp. Among them, ( E )- N -hydroxy-6-(2-(3-nitrobenzylidene)hydrazine-1-carbothioamido)hexanamide could significantly inhibit K562/A02 cells proliferation with an IC 50 value of 0.96 μM. Interestingly, ( E )-
P-糖蛋白(P-gp)过度表达被认为是白血病多药耐药(MDR)和化疗失败的主要原因。在这项研究中,制备了 17 种含缩氨基硫脲的化合物,并将其评估为潜在的抗白血病药物,以对抗过度表达 P-gp 的耐药性 K562/A02 细胞。其中,(E)-N-羟基-6-(2-(3-nitrobenzylidene)hydrazine-1-carbothioamido)己酰胺能显着抑制K562/A02细胞增殖,IC 50 值为0.96 μM。有趣的是,(E)-N-羟基-6-(2-(3-nitrobenzylidene)hydrazine-1-carbothioamido)hexanamide 可以剂量依赖性地增加耐药 K562/A02 细胞的 ROS 水平,从而显示出潜在的附带敏感性(CS )-诱导作用和选择性杀死 K562/A02 细胞。此外,( E )- N-hydroxy-6-(2-(3-nitro